Alerts will be sent to your verified email
Verify Email
BETA
|
Beta Drugs
|
Zenotech Laboratorie
|
Cipla
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
21.02 % | 7.83 % | 12.48 % |
|
5yr average Equity Multiplier
|
1.82 | 1.26 | 1.31 |
|
5yr Average Asset Turnover Ratio
|
0.97 | 0.33 | 0.78 |
|
5yr Avg Net Profit Margin
|
11.94 % | -17.58 % | 12.29 % |
|
Price to Book
|
0.0 | 6.27 | 4.9 |
|
P/E
|
44.64 | 69.78 | 30.44 |
|
5yr Avg Cash Conversion Cycle
|
4.72 Days | 36.89 Days | -4.58 Days |
|
Inventory Days
|
40.73 Days | 145.01 Days | 58.34 Days |
|
Days Receivable
|
86.71 Days | 61.38 Days | 45.49 Days |
|
Days Payable
|
110.62 Days | 477.06 Days | 110.05 Days |
|
5yr Average Interest Coverage Ratio
|
11.36 | -4.03 | 33.93 |
|
5yr Avg ROCE
|
25.44 % | 7.95 % | 17.45 % |
|
5yr Avg Operating Profit Margin
|
21.55 % | 12.81 % | 23.6 % |
|
5 yr average Debt to Equity
|
0.31 | 0.12 | 0.07 |
|
5yr CAGR Net Profit
|
30.75 % | n/a | 21.66 % |
|
5yr Average Return on Assets
|
11.68 % | 7.07 % | 9.64 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
66.73 % | 68.84 % | 30.91 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.05 % | 0.0 | -5.81 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 4.26 % |
|
Beta Drugs
|
Zenotech Laboratorie
|
Cipla
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
Location Wise Break-Up
|